Abstract
Dilated cardiomyopathy (DCM) is accompanied by an impaired cardiac energy metabolism. The aim of this study was to investigate metabolic ratios in patients with DCM compared to controls by using spectroscopic two-dimensional chemical shift imaging (2D-CSI). Twenty volunteers and 15 patients with severe symptoms (left ventricular ejection fraction, LVEF<30%) and ten patients with moderate symptoms (LVEF>30%) of DCM were investigated. Cardiac 31P MR 2D-CSI measurements (voxel size: 40×40×100 mm3) were performed with a 1.5 T whole-body scanner. Measurement time ranged from 15 min to 30 min. Peak areas and ratios of different metabolites were evaluated, including high-energy phosphates (PCr, ATP), 2,3-diphosphoglycerate (2,3-DPG) and phosphodiesters (PDE). In addition, we evaluated how PCr/ATP ratios correlate with LVEF as an established prognostic factor of heart failure. The PCr/γ-ATP ratio was significantly decreased in patients with moderate and severe DCM and showed a linear correlation with reduced LVEFs. PDE/ATP ratios were significantly increased only in patients with severe DCM as compared to volunteers. Applying 31P MRS with commonly-available 2D-CSI sequences is a valuable technique to evaluate DCM by determining PCr/ATP ratios noninvasively. In addition to reduced PCr/ATP ratios observed in patients suffering from DCM, significantly-increased PDE/ATP ratios were found in patients with severe DCM.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fatkin D, Graham RM (2002) Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 82:945–980
Bottomley PA (1994) MR spectroscopy of the human heart: the status and the challenges. Radiology 191:593–612
Ingwall JS (1982) Phosphorus nuclear magnetic resonance spectroscopy of cardiac and skeletal muscles. Am J Physiol 242:729–744
Schaefer S, Gober J, Valenza M, Karczmar GS, Matson GB, Camacho SA, Botvinick EH, Massie B, Weiner MW (1988) Nuclear magnetic resonance imaging-guided phosphorus-31 spectroscopy of the human heart. J Am Coll Cardiol 12:1449–1455
Schaefer S, Massie B, Weiner MW (1989) Magnetic resonance spectroscopy of the heart. Cardiol Clin 7:697–712
Sandstede JJ (2003) Assessment of myocardial viability by MR imaging. Eur Radiol 13:52–61
Schaefer S, Gober JR, Schwartz GG, Twieg DB, Weiner MW, Massie B (1990) In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease. Am J Cardiol 65:1154–1161
Auffermann W, Chew WM, Wolfe CL, Tavares NJ, Parmley WW, Semelka RC, Donnelly T, Chatterjee K, Higgins CB (1991) Normal and diffusely abnormal myocardium in humans: functional and metabolic characterization with P-31 MR spectroscopy and cine MR imaging. Radiology 179:253–259
Masuda Y, Tateno Y, Ikehira H, Hashimoto T, Shishido F, Sekiya M, Imazeki Y, Imai H, Watanabe S, Inagaki Y (1992) High-energy phosphate metabolism of the myocardium in normal subjects and patients with various cardiomyopathies—the study using ECG gated MR spectroscopy with a localization technique. Jpn Circ J 56:620–626
Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G (1991) Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 122:795–801
Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K et al (1992) 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86:1810–1818
Bottomley PA, Hardy CJ (1992) Proton overhauser enhancements in human cardiac phosphorus NMR spectroscopy at 1.5 T. Magn Reson Med 24:384–390
Loffler R, Sauter R, Kolem H, Haase A, von Kienlin M (1998) Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans. J Magn Reson 134:287–299
Meininger M, Landschuetz W, Beer M, Seyfarth T, Horn M, Pabst T, Haase A, Hahn D, Neubauer S, von Kienlin M (1999) Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy. Magn Reson Med 41:657–663
Rector TS, Cohn JN (1994) Prognosis in congestive heart failure. Annu Rev Med 45:341–350
Schaefer S (1990) Clinical nuclear magnetic resonance spectroscopy: insight into metabolism. Am J Cardiol 66:45–50
Krahe T, Schindler R, Neubauer S, Ertl G, Horn M, Lackner K (1993) 31P-cardio-MR-spectroscopy in myocardial insufficiency. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 159:64–70
Schindler R, Krahe T, Neubauer S, Hillenbrand H, Entzeroth C, Horn M, Lackner K, Ertl G (1992) The direct measurement of the spin-grid-relaxation times of phosphorus metabolites in the human myocardium. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 157:452–457
Ye Y, Gong G, Ochiai K, Liu J, Zhang J (2001) High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation 103:1570–1576
Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281:1309–1312
Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K (1997) Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96:2190–2196
van Dobbenburgh JO, Lekkerkerk C, van Echteld CJ, de Beer R (1994) Saturation correction in human cardiac 31P MR spectroscopy at 1.5 T. NMR Biomed 7:218–224
Acknowledgement
The authors thank Ines Krumbein and Urte Jäger for excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hansch, A., Rzanny, R., Heyne, JP. et al. Noninvasive measurements of cardiac high-energy phosphate metabolites in dilated cardiomyopathy by using 31P spectroscopic chemical shift imaging. Eur Radiol 15, 319–323 (2005). https://doi.org/10.1007/s00330-004-2504-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-004-2504-0